To view the fulltext, please log in
To view the pdf, please log in
Background: The cerebral β-amyloid (Aβ) disorders show a great variability in the distribution of parenchymal and vascular amyloid deposits. Objective: To study the relationship between amyloid deposition and inflammatory responses in three distinct subtypes of cerebral Aβ disorders. Methods: The distribution of inflammatory proteins and cells in vascular and plaque amyloid deposits was evaluated in postmortem brain tissue using immunohistochemistry. The effects of a mixture of Aβ peptides and inflammation-related Aβ-associated proteins were studied in postmortem obtained human microglia cell cultures. Results: The chronic inflammatory response is associated with amyloid plaques (but not with amyloid in the walls of larger vessels) in Alzheimer’s disease (AD), with amyloid in cerebral arteries in hereditary cerebral hemorrhage with amyloidosis-Dutch type and with amyloid microangiopathy in the vascular variant of AD. Aβ1–42 fibrils complexed with complement factor C1q and serum amyloid P component (the relevant amyloid-associated proteins) stimulate the production of proinflammatory cytokines in human microglia cell cultures and this production is attenuated by minocycline. Conclusion: The pattern of the chronic inflammatory response associated with fibrillar Aβ is strikingly different in the three studied types of Aβ disorders. The site of the fibrillar Aβ-induced chronic inflammatory response is closely related to clinical symptoms. Minocycline is a drug of interest to inhibit microglia-mediated neuroinflammatory response in Aβ brain disorders.
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Yamada M, Itoh Y, Suematsu N, Otomo E, Matsushita M: Vascular variant of Alzheimer’s disease characterized by severe plaque-like β-protein angiopathy. Dement Geriatr Cogn Disord 1997;8:163–168.
- Veerhuis R, van Breemen MJ, Hoozemans JJM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P: Amyloid-β-associated proteins C1q and SAP enhance the Aβ1–42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol 2003;105:135–144.
- Maat-Schieman ML, van Duinen SG, Rozemuller AJM, Haan J, Roos RAC: Association of vascular amyloid-β and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer’s disease. J Neuropathol Exp Neurol 1997;56:273–284.
- Rozemuller AJM, van Gool WA, Eikelenboom P: The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer’s disese: therapeutic implications. Curr Drug Targets CNS Neurol Disord 2005;4:223–233.
- Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Stüchler-Pierrat C, Büki K, van Duinen SG, Maat-Schieman MLC, Staufenbiel, M, Mathews PM, Jucker C: Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004;7:954–960.
- Miao J, Xu F, Davis J, Otte-Höller, Verbeek MM, Van Nostrand WE: Cerebral microvascular amyloid-β protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid β precursor protein. Am J Pathol 2005;167:505–515.
- Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R: Inhibitory effect of minocycline on amyloid-β fibril formation and microglia activation. Glia 2006;53:223–240.
- Familian A, Eikelenboom P, Veerhuis R: Minocycline does not affect amyloid-β phagocytosis. Neurosci Lett 2007;416:87–91.
- Fan R, Xu, F, Previti ML, Davis J, Grande AM, Robinson JK, Van Nostrand WE: Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of microvascular amyloid. J Neurosci 2007;27:3057–3063.
- Wilcock DN, Munireddy, SK, Rosenthal A, Ugen KE, Gordon, MN. Morgan D: Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol Dis 2004;15:11–20.